669,046 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 669,046 shares of the biopharmaceutical company’s stock, valued at approximately $24,828,000. Agios Pharmaceuticals comprises about 2.5% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 9th largest position. Parkman Healthcare Partners LLC owned about 1.12% of Agios Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Creative Planning boosted its holdings in Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 280 shares during the last quarter. Assetmark Inc. raised its holdings in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Agios Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock worth $4,393,000 after purchasing an additional 512 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Agios Pharmaceuticals by 3.4% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 662 shares during the period.

Agios Pharmaceuticals Trading Down 1.4%

AGIO opened at $32.64 on Tuesday. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -4.66 and a beta of 0.58. The company’s fifty day moving average price is $35.85 and its two-hundred day moving average price is $31.47.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AGIO has been the subject of a number of analyst reports. Truist Financial lowered their target price on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a research note on Friday, July 31st. HC Wainwright upped their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Bank of America increased their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $41.25.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider owned 54,645 shares of the company’s stock, valued at $1,665,579.60. The trade was a 35.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.